Liquid Biopsy Market Outlook Assessing Future Opportunities And Growth Prospects

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Liquid Biopsy Market Through 2030?

The liquid biopsy market has experienced rapid expansion in recent years. This market is projected to expand from $1.46 billion in 2025 to $1.71 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.3%. The expansion observed during the historic period was driven by factors such as the drawbacks of conventional tissue biopsy methods, the rising global prevalence of cancer, the swift embrace of blood-based diagnostic tools, developments in molecular biology, and a heightened emphasis on detecting cancer early.

The liquid biopsy market size is projected for substantial expansion in the next few years. It is expected to reach $3.11 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.2%. This growth in the forecast period is attributable to increasing demand for precision oncology, wider adoption in routine cancer screening, expanding applications in recurrence monitoring, growth in oncology diagnostic spending, and increasing awareness among clinicians and patients. Major trends during this period include the rising acceptance of non-invasive cancer diagnostics, increased use of liquid biopsy for early cancer detection, a growing need for real-time treatment monitoring, the expansion of liquid biopsy in personalized oncology, and its increasing clinical acceptance as an alternative to tissue biopsy.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

Which Significant Factors Are Encouraging Growth In The Liquid Biopsy Market?

Increased government financial support for advancing cancer detection is a primary catalyst for the expansion of the liquid biopsy market. This governmental funding is largely a response to the escalating global prevalence of cancer, the critical demand for early diagnosis to improve treatment efficacy, and the emphasis on reducing healthcare expenses through innovative diagnostic methods. Such funding benefits liquid biopsy by expediting research and development efforts, providing assistance for clinical trials, and fostering the integration of sophisticated, non-invasive diagnostic technologies, ultimately leading to enhanced early cancer identification and customized treatment approaches. For example, in October 2024, gov.UK, a UK-based government website, reported that £118 ($150.38) million was designated for UK Research and Innovation, with £54 million originating from the government and £64 ($81.55) million contributed by partners. Therefore, the rise in government funding aimed at improving cancer detection is actively driving the growth of the liquid biopsy market.

How Is The Liquid Biopsy Market Examined Through Segment Analysis?

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

Which Trends Are Shaping The Liquid Biopsy Market Landscape?

Leading companies in the liquid biopsy market are focusing on developing innovative solutions, such as comprehensive circulating tumor DNA (ctDNA) genomic-profiling assays. These initiatives aim to accelerate noninvasive cancer profiling, facilitate faster therapeutic decision-making, and broaden access to precision oncology, particularly where tissue is limited or unobtainable. A ctDNA comprehensive genomic-profiling assay examines fragments of tumor-derived cell-free DNA found in blood to identify somatic small variants, copy-number changes, insertions/deletions, and immuno-oncology signatures (e.g., bTMB and bMSI), thereby offering more extensive tumor insight without the invasiveness, sampling bias, and longer turnaround time associated with traditional tissue biopsies. For example, in November 2023, Illumina Inc., a US-based sequencing and genomics company, launched TruSight Oncology 500 ctDNA v2. This research-use liquid biopsy panel for noninvasive genomic profiling of solid tumors integrates an expanded hybrid-capture panel with DRAGEN bioinformatics to sequence 523 biomarkers from low cfDNA input. The assay enriches and detects SVs, CNVs, indels, and immuno-oncology metrics with high analytical performance, provides streamlined workflows involving a single hybridization step and a less than 4-day turnaround, and is compatible with NovaSeq systems and upcoming automation. It supports usage when tissue is unavailable or delayed, complements tissue testing, and enables broad pan-cancer research and trial screening, offering faster insights, suitability for low-input samples, and easier adoption across distributed lab environments.

Who Are The Key Market Participants In The Liquid Biopsy Market?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Access The Complete Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

What Is The Largest Regional Market In The Liquid Biopsy Market?

North America was the largest region in the liquid biopsy market in 2025. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Liquid Biopsy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=2815&type=smp

Browse Through More Reports Similar to the Global Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Biopsy Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795